From researchers to researchers

Our team took the challenge of integrating a bioprinting system within a hospital setting, and we were fortunate to find Regemat 3D as the only company being able to adapt their system to all our diverse necessities. Their bioprinters allowed us to expand our collaborative nature, working with various research groups in the areas of skin bioprinting, bone regeneration, and 3D cancer models for drug screening. Thanks to the ability to personalize our equipment, not only we achieved optimized results for our experimental workflow, but we also discovered new scientific fields. Our research members were guided by comprehensive technical engineering assistance, during the help process, benefiting from the vast accumulated experience of bioprinting community.

Regemat 3D has developed an efficient and versatile 3D bioprinter. We are using several of its systems in collaboration with the project developed by Cloud Science and the Laboratory of Biomaterials and Bioengineering and Professor Diego Mantovani of the University of Laval, (Quebec City, Canada). We value all the time that the Regemat team has spent with us, understanding our needs and challenges that we face in our research group. Support is constant and close.

We decided to go for Regemat 3D for two main reasons: the closeness and professionalism of its technical team and the personalization of the bioprinter to our technical requirements. In our research group we work in various tissue engineering applications, therefore, we needed a modular system that was adapted to our needs each time.

We are printing different drugs with synthetic and natural polymers for various applications such as cancer therapy, and tissue engineering. Thank you for all your supports.

We were one of the first research groups to acquire a personalized REGEMAT 3D bioprinter and we are very happy to continue working today with such a professional team. They constantly support us solving any technical question. The system is very versatile and has allowed us to achieve great results in publishing our latest paper on bioink development.